Abbott India Ltd
NSE: ABBOTINDIA BSE: 500488
₹26460
(-0.75%)
Sat, 14 Feb 2026, 01:59 pm
Market Cap562.47B
PE Ratio36.89
Dividend1.79
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1944
- Issued all shares to Boots Pure Drug Co., Ltd.; 5 shares for cash.
1963
- Issued 200,000 shares to the company.
1965
- Incorporated on December 15 to manufacture Boots brand medical, pharmaceutical, agricultural, and animal health products.
- Commissioned plant with 1,500 mega units capacity in January.
- Commissioned sterile manufacturing unit for insulin in September.
- Entered technical collaboration with Boots Pure Drug Co. Ltd., England on October 19.
- Issued 200,000 shares to public at premium of Rs 13 per share in December.
1969
- Issued 25,000 shares at par to L.I.C., U.T.I., I.C.I.C.I. on 5% debenture conversion.
1971
- Changed name from Boots Pure Drug Co. (India) Ltd. effective November 1.
- Changed name to Boots Pharmaceuticals Ltd. effective January 1.
1973
- Issued 25,000 shares at par to L.I.C., U.T.I., I.C.I.C.I. on 5% debenture conversion.
1976
- Initiated chemical plant at Ahmednagar for Ibuprofen manufacture.
- Issued 775,000 bonus shares in 1:1 proportion.
1977
- Issued 148,150 right equity shares at premium of Rs 3.50 in 2:9 proportion.
1979
- Issued 266,050 bonus shares in 1:3 proportion.
1983
- Issued 170,000 15% non-convertible debentures of Rs 100 each, redeemed October 1990.
- Boots Company PLC disinvested 300,000 equity shares at premium of Rs 45.
- Issued 427,290 equity shares at premium of Rs 45 as rights.
- Reduced Boots Company PLC holding from 53% to 40%.
1984
- Issued 1,358,520 bonus equity shares in 3:5 proportion.
1986
- Applied for expansion to 200 tonnes Ibuprofen and 300 M.U. insulin.
- Offered 427,280 equity shares as rights at premium of Rs 45 per share.
1987
- Received letter of intent for Ibuprofen and insulin expansions.
- Implemented Ibuprofen expansion capacity.
- Applied for industrial license for Ranitidine Hydrochloride and formulations.
- Issued 4,050,000 bonus equity shares in 1:1 proportion.
1988
- Launched Advene and Froben.
- Initiated project for new formulation factory at Jejuri, Pune.
1989
- Launched Brufen Junior Syrup, Chota Strepsils Icy, Optrex Eye Lotion, Highly Purified Insulins, Nausidome.
1991
- Launched Human Insulins, Frozen SR, Optren Eye Drops.
1994
- Launched Novopen, Human Mixtard, Mixtard Penfills.
- Subsidiaries: Beem Healthcare Ltd., Lenbrook Pharmaceuticals Ltd., Valencia Pharmaceuticals Ltd.
1995
- Changed name to Knoll Pharmaceuticals Ltd. effective October 31.
1997
- Launched Clivarine anticoagulant.
- Acquired Epilex for Rs 9.90 crores.
- Commissioned new Goa plant.
- Lupharma GmbH made public offer for 11% stake.
- Entered co-marketing arrangement with SmithKline Beecham.
1998
- Launched Cremaffin anticoagulant low molecular weight heparin.
- Lupharma GmbH made public offer for 11% stake to reach 51%.
1999
- Merged Beem Healthcare effective July 1998.
- Entered pact with Torrent Pharmaceuticals and Novo Nordisk for human insulin.
2000
- Entered agreement with Kalpataru Homes for leasehold assignment.
- Ranbaxy Laboratories agreed to market brands in select overseas markets.
2001
- Lupharma UK Holding One Ltd. proposed to acquire 51% shares from Lupharma GmbH.
2002
- Changed name to Abbott India following takeover of BASF Pharma by Abbott Laboratories.
2003
- Mr. V. D. Narkar resigned as Director effective June 19.
- Appointed Mr. Ashok Dayal as Additional Director.
- Implemented scheme of amalgamation of Lenbrook Pharmaceuticals with the company.
2008
- Appointed Mr. Thomas Dee as Additional Director.
2009
- Recommended dividend of Rs 14 per share.
2010
- Recommended dividend of Rs 17 per share.
2011
- Recommended dividend of Rs 17 per share.
2012
- Recommended dividend of Rs 17 per share.
2013
- Named Multinational Pharmaceutical Company of the Year for third consecutive year at Frost & Sullivan Awards.
- Announced national hypothyroidism prevalence study results.
2014
- Launched thyroid awareness initiative in Uttar Pradesh and Uttarakhand with Indian Thyroid Society.
- Awarded Golden Peacock Innovation Management Award.
2021
- Launched Pandemic Defense Coalition.
- Launched Brufen Power spray.
- Launched device for treatment of premature babies and newborns with heart openings.
- Launched new Pediasure for catch-up growth in children.
2022
- Announced collaborations for holistic diabetes care.
- Launched Arachitol Gummies for Vitamin D and Calcium.
- Launched Grow Right 2.0 for child growth.
- Launched Ensure with HMB for muscle protection and strength.
- Launched Navitor TAVI system for aortic stenosis.
2023
- Launched Vertigo Coach app.
- Launched Pediasure with Nutri-Pull system.
- Launched vascular imaging platform powered by Ultreon 1.0 Software.
- Launched XIENCE Sierra Everolimus Eluting Coronary Stent System.
2024
- Launched next-generation Xience Sierra stent.
- Launched GLP systems Track automation solutions.
- Inaugurated innovative outreach centers with Yrgcare.
- Launched Aveir Vr leadless pacemaker system.
2025
- Launched new advanced formulation of Ensure Diabetes Care.
- Launched AVEIR dual chamber leadless pacemaker system.
- Introduced lab-based blood test to evaluate concussion.
- Launched next-gen Freestyle Libre 2 Plus with continuous glucose readings and alarms.
- Introduced Navitor Vision in India for aortic stenosis.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800